- Home
- LB vs DYN Comparison
LB vs DYN Comparison
Compare LB & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LB
- DYN
- Stock Information
- Founded
- LB 1992
- DYN 1984
- Country
- LB United States
- DYN United States
- Employees
- LB N/A
- DYN N/A
- Industry
- LB
- DYN Medicinal Chemicals and Botanical Products
- Sector
- LB
- DYN Health Care
- Exchange
- LB NYSE
- DYN Nasdaq
- Market Cap
- LB 1.6B
- DYN 1.4B
- IPO Year
- LB 2024
- DYN 2020
- Fundamental
- Price
- LB $56.70
- DYN $8.28
- Analyst Decision
- LB Buy
- DYN Strong Buy
- Analyst Count
- LB 9
- DYN 15
- Target Price
- LB $62.13
- DYN $43.07
- AVG Volume (30 Days)
- LB 469.1K
- DYN 3.7M
- Earning Date
- LB 08-06-2025
- DYN 08-11-2025
- Dividend Yield
- LB 0.70%
- DYN N/A
- EPS Growth
- LB N/A
- DYN N/A
- EPS
- LB 0.02
- DYN N/A
- Revenue
- LB $134,891,000.00
- DYN N/A
- Revenue This Year
- LB $85.89
- DYN N/A
- Revenue Next Year
- LB $16.76
- DYN N/A
- P/E Ratio
- LB $3,330.46
- DYN N/A
- Revenue Growth
- LB 77.50
- DYN N/A
- 52 Week Low
- LB $26.51
- DYN $6.36
- 52 Week High
- LB $87.60
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- LB N/A
- DYN 32.98
- Support Level
- LB N/A
- DYN $8.06
- Resistance Level
- LB N/A
- DYN $9.27
- Average True Range (ATR)
- LB 0.00
- DYN 0.60
- MACD
- LB 0.00
- DYN -0.06
- Stochastic Oscillator
- LB 0.00
- DYN 8.21
About LB LANDBRIDGE COMPANY LLC
LandBridge Co LLC is engaged in managing land and resources to support and promote oil and natural gas development. It generates revenue streams from the use of its surface acreage, the sale of resources from land and oil and gas royalties.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.